A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
2022-11-27
عنوان الدراسة
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
داعم الدراسة
Astrazeneca
دواء الدراسة
Trastuzumab-deruxtecan
رقم بروتوكول الدراسة
D967RC00001
حالة الدراسة
Ongoing
موقع الدراسة
International Medical Center (Jeddah),King Fahad Specialist Hospital (Dammam)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.